Latest filing published 09 Mar 2026 for Teva Pharmaceutical Industries Ltd. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Eliyahu Sharon Kalif (senior executive) discloses dealings in Teva Pharmaceutical Industries Ltd to SEC (Form 4). Between 13 February 2022 and 5 March 2026, the trades on record add up to 20 filings.
On the market, this insider has only sold: 5 sales, €12.4M in total. Besides market trades, the filings include 15 option exercises. Since January 2026: no purchases and 1 sale on the market.
The record was last updated on 9 March 2026 with an option exercise in Teva Pharmaceutical Industries Ltd. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
20 of 20 declarations